Design, synthesis, and biological evaluation of new territrem B analogues. 2005

Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
Department of Traditional Chinese Medicine and Natural Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310031, PR China.

Some 23 analogues of the potent acetylcholinesterase (AChE) inhibitor territrem B (1) were designed, synthesized, and tested for their biological activities. Some of the new synthetic derivatives exhibited IC50 values for AChE inhibition in the upper micromolar range. Molecular-modeling studies indicated that a planar conformation seems to be crucial for AChE inhibition. The two N-atoms of the piperazine moieties in 5o, 5p, and 5r might further enhance the inhibitory effects. The cytotoxicities of selected compounds against six human tumor cell lines were also determined.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011714 Pyrans Pyran
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
February 2006, Organic letters,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
June 2013, Yao xue xue bao = Acta pharmaceutica Sinica,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
February 2021, Bioorganic & medicinal chemistry letters,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
May 2018, Bioorganic & medicinal chemistry,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
January 2016, Chemical & pharmaceutical bulletin,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
May 2016, ChemMedChem,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
January 2010, Bioinorganic chemistry and applications,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
March 2007, Archiv der Pharmazie,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
January 2013, Journal of medicinal chemistry,
Xiangrui Jiang, and Lei Ao, and Changxin Zhou, and Leixiang Yang, and Qijun Zhang, and Haibo Li, and Lianli Sun, and Xiumei Wu, and Hua Bai, and Yu Zhao
July 2007, The Journal of organic chemistry,
Copied contents to your clipboard!